Pharmacy Times
AUGUST 10, 2024
Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.
STAT
AUGUST 10, 2024
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
AUGUST 10, 2024
The commencement of the phase 1 clinical trial of SAT-3247 is expected in Q3 of 2024.
Drug Topics
AUGUST 10, 2024
Check out this recap of articles published on our sister sites during the past week.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioPharm
AUGUST 10, 2024
AAV and lentivirus both have pros and cons in their use for specific gene therapy applications.
Drug Topics
AUGUST 10, 2024
Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.
The Honest Apothecary
AUGUST 10, 2024
“Yep, son, we have met the enemy, and he is us.” – Walt Kelly The line above comes from “Pogo”, the humble and contemplative opossum from Walt Kelly’s long-running mid-20th century comic strip. Here, Pogo is expressing his acknowledgement and disappointment that from an environmental perspective, we are actually the enemy.
Expert insights. Personalized for you.
153 
Let's personalize your content